Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) AI Stock Analysis

• Market Cap: HK$16.90B
• Dividend Yield: 5.23%
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): 14.0
• Beta (1Y): 0.95
• Revenue Growth: -1.40%
• EPS Growth: N/A
• Country: HK
• Employees: 1,926
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.10
• Shares Outstanding: 220,094,500
• 10 Day Avg. Volume: 947,650
• 30 Day Avg. Volume: 1,161,300
• PEG Ratio: -0.05
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 1.03
• P/FCF Ratio: 2.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.66
• Revenue Forecast (FY): HK$6.94B

• Rating: 68 Neutral
• Price Target: HK$6.00 ▲(15.61% Upside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

The score is primarily driven by improving financial stability and profitability (but with margin compression and uneven recovery), complemented by reasonable valuation supported by a ~4.8% dividend yield. Technicals are positive on trend (price above major moving averages) but are held back by an overbought RSI signal.

Positive Factors

Manageable leverage

A low debt-to-equity (~0.25) materially enhances financial resilience, reducing refinancing and liquidity risk. This conservative leverage profile supports steady investment in compliance, capacity and R&D for heparin/API production, enabling durable operations and strategic optionality over the medium term.

Solid cash generation

Free cash flow exceeding net income (~1.17x) signals earnings quality and reliable cash conversion. Strong FCF provides sustainable funding for capex, regulatory compliance, dividend support and debt reduction, which are vital for capital-intensive pharma manufacturing and long-term competitiveness.

Return to profitability & revenue growth

A return to profitability and ~5% TTM revenue growth indicates recovery in core heparin demand. Combined API, finished-dosage and CDMO businesses offer diversified, repeatable revenue streams that underpin medium-term cash generation and reduce reliance on any single channel or contract.

Negative Factors

Margin compression

Compression of gross and net margins reduces intrinsic earnings power and constrains free cash available for reinvestment or distributions. If margin pressure is structural—due to pricing, raw-material or mix shifts—it will impair long-term profitability and limit funding for growth or quality compliance investments.

Volatile results historically

Pronounced volatility (sharp 2023 downturn then uneven recovery) weakens forecastability and complicates medium-term planning. For a manufacturing and regulatory-heavy pharma business, inconsistent earnings make capital-allocation decisions and investment in capacity or new registrations riskier for sustaining long-run growth.

Modest shareholder returns / low ROE

Persistently low return on equity suggests the company is not efficiently converting its equity base into strong profits. Over the medium term, modest ROE can limit shareholder value creation, constrain dividend growth and indicate operational or capital-intensity challenges relative to peers.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

How the Company Makes Money

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. generates revenue primarily through the manufacturing and sale of heparin-based products, including APIs and finished dosage forms. These products are supplied to pharmaceutical companies, hospitals, and healthcare providers around the world. The company also engages in contract manufacturing services, leveraging its advanced production facilities and expertise to produce drugs on behalf of other pharmaceutical firms. Additionally, Hepalink has strategic partnerships and collaborations with international biopharmaceutical companies, which expand its product offerings and market reach. Licensing agreements and royalties from proprietary technologies and products further contribute to its revenue streams.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Statement Overview

Summary

Financials indicate a stable recovery: TTM returned to profitability with ~5% revenue growth and a conservatively levered balance sheet (debt-to-equity ~0.25). Offsetting this are margin compression from 2024 to TTM, uneven results vs prior years, and modest recent returns on equity, suggesting profitability is improving but not yet firmly re-established.

Income Statement

TTM (Trailing-Twelve-Months) shows a return to profitability with positive operating profit and net income, and revenue growth of about 5%. However, profitability is well below prior peaks (e.g., 2020) and has compressed from 2024 to TTM (lower gross and net margins). Results also look less consistent over time, with a sharp downturn in 2023 followed by recovery.

Balance Sheet

Leverage looks manageable with debt-to-equity around 0.25 in both 2024 and TTM (Trailing-Twelve-Months), an improvement versus earlier years when leverage was materially higher. Equity has grown, supporting balance sheet resilience. The main weakness is modest shareholder returns recently (low return on equity in TTM and 2024), indicating the capital base is not currently generating strong profitability.

Cash Flow

Cash generation is a relative bright spot: TTM (Trailing-Twelve-Months) free cash flow exceeds net income (about 1.17x), suggesting earnings quality is reasonable. That said, free cash flow growth turned negative in TTM after strong growth in 2024, and operating cash flow coverage is not especially strong, pointing to some volatility in cash conversion and working-capital dynamics.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2020
Income Statement
Total Revenue	5.41B	5.28B	5.45B	7.16B	6.37B	5.33B
Gross Profit	1.73B	1.76B	1.80B	2.33B	2.03B	2.09B
EBITDA	658.44M	1.20B	―	1.37B	726.64M	1.88B
Net Income	553.53M	646.74M	―	727.43M	240.79M	1.02B
Balance Sheet
Total Assets	17.13B	17.34B	19.20B	20.81B	19.11B	19.03B
Cash, Cash Equivalents and Short-Term Investments	3.08B	2.56B	2.27B	3.45B	3.93B	3.54B
Total Debt	3.08B	2.98B	3.78B	6.46B	5.65B	5.65B
Total Liabilities	4.70B	5.14B	7.22B	8.41B	7.58B	7.34B
Stockholders Equity	12.37B	12.15B	11.91B	12.31B	11.41B	11.57B
Cash Flow
Free Cash Flow	1.71B	1.99B	-46.66M	-979.03M	-200.49M	-175.21M
Operating Cash Flow	1.46B	2.19B	398.22M	-756.61M	-6.63M	37.28M
Investing Cash Flow	-937.96M	-415.05M	1.22B	249.84M	719.93M	-2.17B
Financing Cash Flow	-1.69B	-2.14B	-1.21B	329.56M	-501.08M	2.51B

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9989, the sentiment is Negative. The current price of 5.19 is below the 20-day moving average (MA) of 5.38, below the 50-day MA of 5.31, and below the 200-day MA of 5.55, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.39 is Neutral, neither overbought nor oversold. The STOCH value of 17.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9989.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9989	68 Neutral	HK$16.90B	14.01	3.31%	5.23%	-1.40%	―
3320	68 Neutral	HK$27.64B	3.54	5.90%	2.95%	―	―
0013	53 Neutral	HK$18.37B	2.88	48.58%	―	-1.78%	―
2196	53 Neutral	HK$70.91B	10.98	6.75%	1.69%	-1.12%	76.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6185	47 Neutral	HK$13.23B	292.71	-2.79%	―	29.21%	80.37%

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Corporate Events

Hepalink Sees 2025 Headline Profit Fall on One-Off Base, Underlying Earnings Surge on Heparin Growth

Shenzhen Hepalink Pharmaceutical Group expects its net profit attributable to shareholders for 2025 to decline sharply year on year to approximately RMB284 million–RMB377 million, down about 41.71% to 56.09% from 2024, reflecting the absence of last year’s substantial one-off investment income and the impact from an associate’s weaker-than-expected R&D progress. However, net profit after excluding non-recurring items is forecast to rise significantly to RMB362 million–RMB460 million, an increase of roughly 42.78% to 81.43%, underscoring stronger underlying operations driven by robust growth in the group’s global heparin finished dose and enoxaparin businesses, which are reinforcing Hepalink’s competitive position despite the drag from non-recurring factors.

The most recent analyst rating on (HK:9989) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.

Shenzhen Hepalink Approves Key Governance Changes at EGM

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. held its 2025 first extraordinary general meeting where key resolutions were passed, including the abolition of the supervisory committee and amendments to the company’s articles of association and governance measures. The election of Mr. Pu Hong as an independent non-executive director was also approved, reflecting the company’s efforts to streamline governance and enhance its board’s independence.

The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.

Shenzhen Hepalink Announces Board Composition and Roles

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement outlines the leadership structure, which includes both executive and independent non-executive directors, and details the membership of four key board committees. This update is significant for stakeholders as it provides clarity on the governance and strategic oversight within the company, potentially impacting its decision-making and operational focus.

The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.

Shenzhen Hepalink Proposes Governance Restructuring and Board Changes

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced significant changes to its corporate governance structure. The company proposes to abolish its Supervisory Committee, transferring its responsibilities to the Board’s audit committee, and plans to amend its articles of association and internal governance measures, pending shareholder approval. Additionally, the term of an independent non-executive director, Dr. Lu Chuan, is set to expire, and the company proposes the election of Mr. Pu Hong as his replacement. These changes aim to streamline governance and align with regulatory guidelines, potentially impacting the company’s operational efficiency and stakeholder relations.

The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.

Shenzhen Hepalink Announces 2025 Extraordinary General Meeting

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced the convening of its 2025 first extraordinary general meeting (EGM) on December 16, 2025, in Shenzhen, China. The meeting will address significant corporate governance changes, including the abolition of the supervisory committee and amendments to the articles of association. Additionally, the election of Mr. Pu Hong as an independent non-executive director will be considered. These changes could impact the company’s governance structure and strategic direction, affecting stakeholders and potentially altering its industry positioning.

The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.

Shenzhen Hepalink Releases 2025 Q3 Financial Report

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for 2025, covering the nine months ending September 30, 2025. The report, prepared in accordance with PRC Accounting Standards, was approved by the board of directors, confirming the accuracy and completeness of the financial information. This announcement underscores the company’s commitment to transparency and regulatory compliance, potentially reinforcing investor confidence and maintaining its market position.

The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.